Apremilast, a phosphodiesterase‐4 (PDE4) inhibitor, has proven to be effective for the treatment of oral ulcers in BD through phase‐3 randomized controlled studies [4, 5, 6], but was unavailable in some high‐prevalence countries, including Turkey and Korea, at the time of the study [7]. This evidence concerns the gene PDE4A and Behcet disease.